Forsta AP Fonden Has $16.94 Million Position in DexCom, Inc. $DXCM

Forsta AP Fonden increased its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 157.6% in the 4th quarter, HoldingsChannel.com reports. The firm owned 255,300 shares of the medical device company’s stock after purchasing an additional 156,200 shares during the quarter. Forsta AP Fonden’s holdings in DexCom were worth $16,944,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also added to or reduced their stakes in the company. Norges Bank acquired a new position in DexCom in the 4th quarter valued at $483,356,000. Eurizon Capital SGR S.p.A. acquired a new position in DexCom in the 4th quarter valued at $3,231,000. Hillsdale Investment Management Inc. acquired a new position in DexCom in the 4th quarter valued at $883,000. Fideuram Asset Management Ireland dac acquired a new position in DexCom in the 4th quarter valued at $3,815,000. Finally, National Pension Service raised its holdings in DexCom by 10.4% in the 4th quarter. National Pension Service now owns 618,615 shares of the medical device company’s stock valued at $41,057,000 after acquiring an additional 58,262 shares in the last quarter. 97.75% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts have weighed in on the company. Raymond James Financial set a $81.00 price objective on DexCom in a report on Friday, May 1st. Truist Financial reaffirmed a “buy” rating and issued a $80.00 price objective (down from $82.00) on shares of DexCom in a report on Tuesday, February 17th. BTIG Research reaffirmed a “buy” rating and issued a $85.00 price objective on shares of DexCom in a report on Monday, March 9th. Robert W. Baird set a $80.00 price objective on DexCom in a report on Friday, May 1st. Finally, Mizuho set a $75.00 price objective on DexCom in a report on Friday, May 1st. Three analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, DexCom has an average rating of “Moderate Buy” and a consensus price target of $82.42.

Insider Activity

In other news, insider Kevin R. Sayer sold 26,759 shares of DexCom stock in a transaction on Thursday, May 21st. The stock was sold at an average price of $72.00, for a total value of $1,926,648.00. Following the transaction, the insider owned 382,482 shares in the company, valued at approximately $27,538,704. This trade represents a 6.54% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bridgette P. Heller sold 1,012 shares of DexCom stock in a transaction on Tuesday, May 12th. The shares were sold at an average price of $60.01, for a total value of $60,730.12. Following the completion of the transaction, the director owned 25,007 shares in the company, valued at approximately $1,500,670.07. The trade was a 3.89% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 32,871 shares of company stock worth $2,306,638. Insiders own 0.28% of the company’s stock.

DexCom Trading Up 1.9%

Shares of DXCM opened at $73.74 on Friday. DexCom, Inc. has a 52-week low of $54.11 and a 52-week high of $89.98. The business’s fifty day moving average is $64.17 and its 200-day moving average is $66.44. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.64 and a current ratio of 1.95. The firm has a market cap of $28.45 billion, a price-to-earnings ratio of 31.51, a PEG ratio of 1.22 and a beta of 1.40.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Thursday, April 30th. The medical device company reported $0.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.47 by $0.09. DexCom had a return on equity of 33.33% and a net margin of 19.31%.The company had revenue of $1.19 billion for the quarter, compared to analyst estimates of $1.17 billion. During the same quarter last year, the company posted $0.32 EPS. The company’s revenue for the quarter was up 15.0% compared to the same quarter last year. Equities analysts anticipate that DexCom, Inc. will post 2.57 EPS for the current fiscal year.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.